Phase I study of an Epstein-Barr Virus (EBV) in healthy volunteers. The vaccine works by targeting EBV glycoprotein gp350, which is found on the surface of the virus and virus-infected cells. EBV gp350 is also the primary target for neutralizing antibodies found in the blood of people naturally infected with EBV. The study is recruiting 40 healthy adults age 18-29.
https://nihrecord.nih.gov/2022/05/27/ni ... rr-vaccine
It’s been 2.5 years since the study was posted to ClinicalTrials.gov and it’s still in the recruiting status.
https://www.clinicaltrials.gov/ct2/show ... w=2&rank=1
Epstein-Barr Virus Vaccine, Phase I
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1719 Views
-
Last post by Tif
-
- 1 Replies
- 319 Views
-
Last post by Leonard
-
- 2 Replies
- 916 Views
-
Last post by DIM
-
- 0 Replies
- 1361 Views
-
Last post by Tif
-
- 0 Replies
- 1938 Views
-
Last post by Tif
-
- 0 Replies
- 1480 Views
-
Last post by Tif
-
- 1 Replies
- 1120 Views
-
Last post by 1eye
-
- 4 Replies
- 2423 Views
-
Last post by NHE
-
- 0 Replies
- 1677 Views
-
Last post by DIM